X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Addressing data challenges to improve health equity

By Emily Donaldson  |    September 17, 2021
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to...   Read More

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

By Joseph Havey  |    September 8, 2021
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve...   Read More

Patients and innovators lose if the government pursues ‘march-in’

By Megan Van Etten  |    September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...   Read More

The impact of monoclonal antibodies and COVID-19 recovery

By Andrew Powaleny  |    September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...   Read More

Recognizing National Immunization Awareness Month

By Richard Moscicki, M.D.  |    August 31, 2021
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...   Read More

PDUFA VII is critical for future biopharmaceutical innovation and for patients

By Richard Moscicki, M.D.  |    August 23, 2021
Today, the U.S. Food and Drug Administration (FDA or Agency) released its performance goals letter for the seventh installment of the Prescription Drug User Fee Act (PDUFA).   Read More

Recognizing Hepatitis R&D on World Hepatitis Day

By Andrew Powaleny  |    July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...   Read More

We Work for Health: Discovering champions, even amid challenging times

By Ryan Garofalo  |    July 26, 2021
For over a decade, We Work For Health has sought to highlight the incredible men and women who create hope for patients, serve as changemakers and ensure the continued vibrancy of our economy. We...   Read More

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

By Tim McClung  |    July 22, 2021
PhRMA member companies’ robust investment in research and development (R&D) has led to advances and discoveries that are transforming health care and our approach to treating patients for a broad...   Read More

3 things that support robust biopharmaceutical research and development

By Richard Moscicki, M.D.  |    June 29, 2021
Rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, many of the most challenging diseases, including cancer,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates